Category
With more than 2,000 dead in what may become the second-largest Ebola epidemic ever, WHO is moving to test Merck’s Ervebo vaccine in a Phase 3 trial in Congo.
Cleared for adults 50 and older, the shot cut confirmed influenza by 27% versus a standard vaccine in 50-to-64-year-olds — a landmark for mRNA beyond COVID.
The contract-research giant will help move Medigen’s broader enterovirus vaccine toward clinical trials, building on an EV71 shot already approved in Taiwan and Vietnam.
By deliberately removing the antibody response that can backfire against dengue, researchers built an experimental Zika vaccine that defended mice using T cells instead.
Older adults who got the Shingrix vaccine had notably lower dementia rates over four years, adding to a growing body of intriguing but not-yet-conclusive evidence.
Analyzing antibody “fingerprints” across thousands of people, a deep-learning model spotted markers that flag who is likely to mount a weak vaccine response in advance.
European regulators have validated the marketing application for a six-valent Lyme vaccine that showed more than 70% efficacy in a 9,437-person Phase 3 trial. No human Lyme vaccine is currently approved.
The Phase 3 PreVenTB study of more than 12,000 people found the vaccines helped only certain groups against certain forms of tuberculosis — underscoring how hard a better TB shot remains.
The personalized vaccine plus Keytruda cut the risk of melanoma returning after surgery — the first positive Phase 3 result for an mRNA-based, individualized cancer vaccine.